Complete Story
05/20/2026
Recent Oncology Related FDA Approvals and Expanded Indications
FDA approves BeOne's sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantel cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor
FDA approves Taiho's INQOVI plus Venetoclax for adults with newly diagnosed acute myeloid leukemia (AML) aged 75 or older or ineligible for intensive induction chemotherapy
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
